Open AccessPIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report
Author(s) -
Guillermo Valencia,
Patricia Rioja,
Zaida Morante,
Jhajaira M. Araujo,
Heberth Daniel Vallejos,
Henry Guerra,
Henry Leonidas Gómez
Publication year - 2021
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v12.i8.702
Subject(s) - medicine , triple negative breast cancer , oncology , capecitabine , breast cancer , biomarker , chemotherapy , radiation therapy , stage (stratigraphy) , neoadjuvant therapy , metastatic breast cancer , biopsy , disease , liquid biopsy , cancer , colorectal cancer , biology , paleontology , biochemistry , chemistry
Currently, the detection of PIK3CA mutations is of special interest in personalized medicine because it is frequently found in triple-negative breast cancer (TNBC). The PI3KCA mutation is an independent negative prognostic factor for survival in metastatic breast cancer, and its prognostic value in liquid biopsy as a biomarker of treatment and early relapse is under investigation, both for metastatic disease and neoadjuvant scenario with curative intent.